<DOC>
	<DOC>NCT00368173</DOC>
	<brief_summary>STUDY OBJECTIVE To evaluate the safety, tolerability, and efficacy, as growth velocity (statural growth), of rhIGF-I/rhIGFBP-3 administered for 12 months in pre-pubertal children and adolescents with GHIS. STUDY DESIGN This study is an open-label, multi-center clinical trial to evaluate the safety and effectiveness of rhIGF-I/rhIGFBP-3 to increase rate of growth when administered once daily for 12 months in children and adolescents with growth hormone insensitivity syndrome (GHIS) such as Laron Syndrome. At the end of the initial twelve-month treatment period, additional safety and long-term efficacy data will be assessed in a second 12 month treatment period.</brief_summary>
	<brief_title>IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Laron Syndrome</mesh_term>
	<criteria>1. A diagnosis of GHIS such as Laron syndrome, 2. 2 18 years of age, 3. Height less than or equal to 3SD for age, 4. Prepubertal, defined as Tanner breast stage 1 or testis volume &lt;4mL 1. Children in puberty, 2. Diagnosed malignancy, 3. A diagnosis of diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>